BiotechTube
Home/EndoLipiD Therapeutics/Rafael Simó, MD, Prof
RS

Rafael Simó, MD, Prof

CMO

EndoLipiD Therapeutics

Therapeutic Areas

MetabolicCardiovascularAesthetic

EndoLipiD Therapeutics Pipeline

DrugIndicationPhase
EDL6DNASH (Non-alcoholic steatohepatitis)Preclinical
EDL81 (Ac-EDL67)CellulitePreclinical

Leadership Team at EndoLipiD Therapeutics

GD
Giacomo de Simone, PhD
CEO
DM
David M. Selva, PhD
CSO, Board Member
AS
Agustí Soler
CFO
View full EndoLipiD Therapeutics profile